Here are 1-3 brief analogies for Establishment Labs (ESTA):

• It's like the Medtronic of breast implants.
• Think of it as the Allergan of modern breast implants.

• Motiva Implants: Silicone gel-filled breast implants.
• Motiva Ergonomix and Motiva Ergonomix2: Gravity sensitive round soft silicone-gel-filled breast implants.
• Motiva Flora Tissue Expander: A breast tissue expander.
• Puregraft line of products: Products for autologous adipose tissue harvesting and redistribution.

Establishment Labs (ESTA) sells its medical devices, such as breast implants and tissue expanders, primarily to other companies and organizations within the healthcare sector, rather than directly to individual consumers.

Based on the provided company description, its major customers fall into the following categories:

• Exclusive Distributors: Establishment Labs utilizes a network of exclusive distributors across Europe, Latin America, the Asia-Pacific, and other international markets. These distributors purchase products from Establishment Labs and then sell them to medical professionals, clinics, and hospitals in their respective regions. The specific names of these individual distribution companies are not disclosed in the provided background information.
• Medical Professionals and Facilities: The company also employs a direct sales force, which sells products directly to plastic surgeons, aesthetic clinics, and hospitals that perform aesthetic and reconstructive plastic surgery. These entities are direct purchasers of Establishment Labs' products.

As the company operates through a broad network of distributors and direct sales to numerous medical facilities globally, the specific names of major customer companies that are publicly disclosed and account for a significant portion of its revenue are not available in the provided background information or typically in public domains for this business model.

Fillipo "Peter" Caldini, Chief Executive Officer

Fillipo "Peter" Caldini assumed the role of Chief Executive Officer of Establishment Labs in March 2025. Prior to this appointment, he served as the President of the company.

Raj Denhoy, Chief Financial Officer

Raj Denhoy holds the position of Chief Financial Officer at Establishment Labs.

Juan José Chacón-Quirós, Founder, Board Member & Advisor

Juan José Chacón-Quirós founded Establishment Labs in 2004. He served as the Chief Executive Officer and a Board Director from 2004 until his retirement from the CEO position on March 1, 2025, continuing as a board member and active advisor. Mr. Chacón-Quirós has extensive experience in the aesthetics industry, having spent a decade as General Manager of an aesthetic medical device distribution business in Latin America, and previously as Business Development Manager for a plastic and reconstructive surgery clinic in Costa Rica. He is a co-author of over 50 patents related to Medtech, including implantable devices, biocompatible surfaces, RFID, biosensors, 3D technology, and minimally invasive surgical instruments. He was recognized as the Entrepreneur of the Year in Costa Rica in both 2017 and 2018.

Roberto de Mezerville, Chief Technology Officer

Roberto de Mezerville serves as the Chief Technology Officer for Establishment Labs.

Paul Rodio, Chief Operating Officer

Paul Rodio holds the title of Chief Operating Officer at Establishment Labs.

The key risks to Establishment Labs' business are primarily centered around safety outcomes and regulatory scrutiny, its path to sustained profitability and positive cash flow, and the intense competitive landscape against larger medical technology companies.

1. Safety Outcomes and Regulatory Scrutiny: A significant risk stems from the potential for adverse safety outcomes related to breast implants, which could undermine physician confidence and patient demand. Breast implants generally carry risks such as rupture, capsular contracture, and the potential need for future surgeries. The FDA has historically tightened regulations on implants due to concerns about "implant illness," and unfavorable long-term data for Establishment Labs' products could severely impact its market position and brand reputation. Past reports have also questioned the validity of the company's safety studies and alleged problems with implants, drawing scrutiny from regulatory bodies and short-sellers. The industry as a whole faces ongoing concerns, including the association of breast implants with Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

2. Profitability and Cash Flow: Establishment Labs continues to face challenges in achieving sustained profitability and positive cash flow. Despite rapid revenue growth and improving gross margins, the company has operated with negative operating margins due to significant investments in scaling its sales force and product adoption. The company has been burning cash and has not yet proven its ability to sustain itself purely on internal cash flow. If operating losses and negative cash flow persist, Establishment Labs may face investor dilution or constraints on future growth investments, posing a critical financial risk.

3. Scale Disadvantage and Competition: Establishment Labs operates in a highly competitive medical technology niche. Its revenue base is considerably smaller compared to established, larger players like AbbVie's aesthetics division and Johnson & Johnson's MedTech sector, leaving it vulnerable to competitive pressures. These larger competitors have entrenched surgeon relationships and extensive resources, which could challenge Establishment Labs' efforts to scale its U.S. sales force and maintain surgeon adoption of its products and new techniques.

Establishment Labs (symbol: ESTA) primarily operates in the breast aesthetics and reconstruction market with its silicone gel-filled breast implants under the Motiva Implants brand and the Motiva Flora Tissue Expander.

The global addressable market for these main products is substantial:

• For **breast implants**, which include products like Motiva Implants, Motiva Ergonomix, and Motiva Ergonomix2, the global market size was approximately USD 2.25 billion in 2025 and is projected to grow to USD 3.22 billion by 2031, with a compound annual growth rate (CAGR) of 6.18% from 2026 to 2031. Other estimates place the global market at USD 2.8 billion in 2025, growing to USD 5.2 billion by 2033 at a CAGR of 7.7% from 2026 to 2033. North America accounted for a significant portion of this market, holding approximately 40.68% of the global breast implants market share in 2025. Establishment Labs also expects the breast reconstruction market to be roughly the same size as the breast augmentation market, which would effectively double their addressable market once they have approval for reconstruction indications.
• For the **Motiva Flora Tissue Expander**, which falls under the breast tissue expander market, the global market size was estimated at USD 795.0 million in 2025 and is projected to reach USD 1,360.8 million by 2033, growing at a CAGR of 7.0% from 2026 to 2033. Another report estimates the global breast tissue expander market to be valued at US$ 1.4 billion in 2026, reaching US$ 2.3 billion by 2033 at a CAGR of 7.3%. North America leads this market, accounting for approximately 43% of the share in 2025.
• Establishment Labs has also identified a new product category in breast aesthetics related to its Minimally Invasive Augmentation (MIA® System), which represents a total addressable market of USD 4-5 billion.

Here are 3-5 expected drivers of future revenue growth for Establishment Labs (ESTA) over the next 2-3 years:

1. Expansion and Growth in the U.S. Market: Establishment Labs received FDA approval for its Motiva Implants in September 2024 and commenced commercial sales in the United States in October 2024, opening up a significant growth opportunity in one of the world's largest breast implant markets. The U.S. business has shown rapid expansion, with U.S. revenue increasing substantially in the first and second quarters of 2026. Management anticipates the U.S. market to contribute over 30% of total revenue in 2026, a notable increase from approximately 22% in 2025.
2. Growth of the Minimally Invasive Platform: The company's Minimally Invasive Platform, which includes Mia Femtech and Preservé, is a crucial strategic initiative designed to expand beyond traditional implant sales by offering comprehensive, packaged procedures for breast augmentation. This platform has demonstrated significant potential, generating substantial revenue in Q1 and Q2 2026, with expectations to exceed $35 million in revenue for 2026. This approach is attracting new patient demographics and enabling surgeons to enhance procedure throughput and pricing.
3. International Market Penetration, particularly in Asia: Establishment Labs has pursued an "international-first" strategy, successfully expanding its presence to over 85 markets outside the United States. A key driver for future growth is the recent regulatory approval in China, identified as one of the largest and fastest-growing aesthetic markets globally. The company also plans further entries into other significant Asian markets, such as Japan.
4. New Product Launches and Line Extensions: The company is committed to broadening its product portfolio through continuous innovation and additional launches within its minimally invasive offerings, including expanded sizes and supporting tools for Mia and Preservé. Preservé, which launched initially in Brazil in February 2025, with a full U.S. launch expected in 2026, represents a newer product expected to contribute significantly to revenue growth.
5. Expansion into New Surgical Categories: Beyond breast aesthetics, Establishment Labs is exploring pipeline expansion into new areas such as breast reconstruction, with FDA approval pending, which could potentially double its U.S. addressable market. There's also a potential future entry into the gluteal implant market with products like GEM (Minimally Invasive Gluteal Modeling).

Share Issuance

• In April 2023, Establishment Labs priced a public offering of 1,100,000 common shares at $71.50 per share, with expected gross proceeds of approximately $78.7 million. The company also granted underwriters an option to purchase up to an additional 165,000 common shares.
• In November 2024, the company announced a registered direct offering for the purchase of common shares and pre-funded warrants, expecting aggregate gross proceeds of approximately $50 million.

Inbound Investments

• In April 2026, Establishment Labs entered into a new $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. This facility refinances existing debt and provides additional capital to support ongoing operations and future strategic growth initiatives, extending debt maturity until 2031.
• Previously, the company had entered into a $225 million credit facility with Oaktree Capital on April 26, 2022.

Capital Expenditures

• Capital expenditures for the first six months of 2026 totaled $5.5 million.
• In the first quarter of 2022, cash decreased partly due to investments in facility expansion.
• Proceeds from share issuances are intended for general corporate purposes, which include capital expenditures.